NEW YORK, Nov. 6, 2013 /PRNewswire/ -- Delcath Systems, Inc. (DCTH) today reported financial results and operational developments for the fiscal third quarter and nine months ended September 30, 2013. Developments for the quarter and recent weeks subsequent to quarter end are as follows:
•Finalizing plans to initiate a global Phase 2 efficacy and safety study to investigate its Melphalan Hepatic Delivery System (Melphalan HDS) for first-line treatment of patients with unresectable hepatocellular carcinoma (HCC); the U.S. Food & Drug Administration (FDA) granted the Company orphan drug designation for melphalan in the treatment of patients with HCC
Help employers find you! Check out all the jobs and post your resume.
